These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 5527022

  • 1. A computer model for tumor growth and chemotherapy, and its application to L1210 leukemia treated with cytosine arabinoside (NSC-63878).
    Shackney SE.
    Cancer Chemother Rep; 1970 Dec; 54(6):399-429. PubMed ID: 5527022
    [No Abstract] [Full Text] [Related]

  • 2. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA, Hutchison DJ.
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract] [Full Text] [Related]

  • 3. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
    Hoffman GS, Kline I, Gang M, Tyrer DD, Goldin A, Mantel N, Venditti JM.
    Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613
    [No Abstract] [Full Text] [Related]

  • 4. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
    Avery TL, Roberts D.
    Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479
    [No Abstract] [Full Text] [Related]

  • 5. Influence of mitotic cycle inhibitors on the antileukemic activity of cytosine arabinoside (NSC-63878) in mice bearing leukemia L1210.
    Vadlamudi S, Goldin A.
    Cancer Chemother Rep; 1971 Dec; 55(5):547-55. PubMed ID: 5159846
    [No Abstract] [Full Text] [Related]

  • 6. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
    Rose WC, Trader MW, Laster WR, Schabel FM.
    Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules.
    Kline I, Venditti JM, Tyrer DD, Goldin A.
    Cancer Res; 1966 May; 26(5):853-9. PubMed ID: 5936445
    [No Abstract] [Full Text] [Related]

  • 11. Influence of route of administration on antileukemic activity of cytosine arabinoside (NSC-63878) in advanced leukemia L1210 in mice.
    Kline I, Tyrer DD, Gang M, Venditti JM, Goldin A.
    Cancer Chemother Rep; 1968 Apr; 52(3):399-404. PubMed ID: 5670722
    [No Abstract] [Full Text] [Related]

  • 12. Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
    Kline I, Woodman RJ, Gang M, Sirica A, Venditti JM, Goldin A.
    Cancer Chemother Rep; 1972 Jun; 56(3):327-34. PubMed ID: 19051491
    [Abstract] [Full Text] [Related]

  • 13. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
    Buchman VM, Svet-Maoldavsky GJ, Lichinitser MR, Mkheidze DM.
    Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
    [Abstract] [Full Text] [Related]

  • 14. Effect of combined therapy with cytosine arabinoside (NSC-63878) and l,3-bis-(2-chloroethyl)-1-nitrosourea (NSC-409962) on sarcoma 180 and L1210 in vivo.
    Mizuno NS, Humphrey EW.
    Cancer Chemother Rep; 1969 Sep; 53(4):215-21. PubMed ID: 5384462
    [No Abstract] [Full Text] [Related]

  • 15. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
    Bukhman VM, Lichinitser MR, Svet-Moldavskiĭ GIa, Mkheidze DM.
    Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
    [Abstract] [Full Text] [Related]

  • 16. Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo.
    Young RC, Goldberg D, Schein PS.
    Biochem Pharmacol; 1973 Jan 15; 22(2):277-80. PubMed ID: 4763256
    [No Abstract] [Full Text] [Related]

  • 17. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Kline I, Woodman RJ, Gang M, Cysyk RL, Venditti JM.
    Cancer Chemother Rep; 1973 Jan 15; 57(3):291-8. PubMed ID: 4751255
    [No Abstract] [Full Text] [Related]

  • 18. Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210.
    Kobayashi T, Tsukagoshi S, Sakurai Y.
    Gan; 1975 Dec 15; 66(6):719-20. PubMed ID: 1225724
    [No Abstract] [Full Text] [Related]

  • 19. [Clinical and animal experiment studies on the cell-cycle arrest using cytosine arabinoside in leukemias].
    Büchner T, Barlogie B, Hiddemann W, Hofschröer J, Metz U, Ortheil NB, Kamanabroo D, Asseburg U.
    Verh Dtsch Ges Inn Med; 1975 Dec 15; 81():1112-4. PubMed ID: 1065151
    [No Abstract] [Full Text] [Related]

  • 20. Computer simulation of leukemia therapy: combined pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of L1210 leukemia by cytosine arabinoside.
    Lincoln T, Morrison P, Aroesty J, Carter G.
    Cancer Treat Rep; 1976 Dec 15; 60(12):1723-39. PubMed ID: 1026330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.